Related Experiment Video

Updated: Dec 31, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Synergistic anticancer effect of Grb2 and ITGA1 on cancer cells highly expressing Grb2 through suppressing ERK

Qingxia Ma1, Jingyi Song1, Hailong Ma2

  • 1School of Basic Medical Sciences, Qingdao University Qingdao, China.

International Journal of Clinical and Experimental Pathology
|January 15, 2020
PubMed
Abstract

Insights

Growth factor receptor bound protein 2 (Grb2) inhibition, alongside ITGA1, synergistically reduces cancer cell proliferation and triggers apoptosis via the ERK pathway. This dual targeting offers a promising therapeutic strategy for cancers with high Grb2 expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Growth factor receptor bound protein 2 (Grb2) is an adaptor protein linking cell surface receptors to MAPK signaling.
  • Elevated Grb2 expression promotes cancer cell proliferation, invasion, and malignant transformation.

Purpose of the Study:

  • To comprehensively investigate the functional role of Grb2 in cancer.
  • To explore potential therapeutic targets for Grb2-associated cancers.

Main Methods:

  • Analyzed Grb2 expression in cancer cell lines using public databases.
  • Investigated Grb2 function in highly expressing Hela and Jurkat cells.
  • Performed proteomic profiling to understand Grb2's cellular impact.

Main Results:

  • Grb2 downregulation reduced proliferation in Hela and Jurkat cells.
  • Grb2 knockdown decreased ITGA1 expression and ERK phosphorylation.
  • Combined Grb2 and ITGA1 inhibition enhanced ERK inhibition and induced apoptosis.

Conclusions:

  • Grb2 and ITGA1 exhibit synergistic anticancer effects mediated by the ERK pathway.
  • Inhibiting Grb2 and ITGA1 presents a potential therapeutic strategy for cancers with high Grb2.
  • Targeting Grb2 and ITGA1 warrants further investigation for cancer treatment.
Keywords:
ERKGrb2ITGA1cancer

More Related Videos

A High-content Imaging Workflow to Study Grb2 Signaling Complexes by Expression Cloning10:52

A High-content Imaging Workflow to Study Grb2 Signaling Complexes by Expression Cloning

Published on: October 30, 2012

11.0K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K